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STATISTICAL DATA ANALYSIS OF DIAGNOSIS RELATED GROUP 244: 
BONE DISEASES AND SPECIFIC ARTHROPATHIES WITH 
COMPLICATIONS
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OBJECTIVES: To examine data for patients with DRG code 244 and compare that 
data to a control group of patients in order to identify statically signiﬁcant variations 
amongst the groups. METHODS: A data set was obtained from the 2006 Healthcare 
Cost and Utilization Project (HCUP) Kids’ Inpatient Database (KID) consisting of 562 
patients. The data included 281 patients with DRG code 244 and an additional 281 
patients for the control group which was made up of patients with orthopaedic, mental 
health, and substance abuse DRG codes other than 244. These data were analyzed 
using SAS Enterprise Guide. RESULTS: Analysis of frequency counts discovered a 
signiﬁcantly lower percentage of Caucasians in the study group (just 38%) when 
compared with the control group’s 66%. African Americans in particular showed the 
greatest increase in patients for the study group with 36% of the study group consist-
ing of African Americans in comparison to just 13% of the control group. Addition-
ally, females represented a lower percentage in the study group. These observations 
were veriﬁed to be statistically signiﬁcant via logistic regression. Additionally, linear 
regression models showed patients in the highest income quartile had signiﬁcantly 
higher total charges than patients in lower income ranges. The wide range of ICD-9 
diagnosis codes indicated that DRG 244 consists of a broad group of loosely related 
conditions. CONCLUSIONS: The statistical analysis veriﬁed that many bone related 
diseases are much more prevalent in patients with darker skin tone, and more melanin 
in their skin. This supports current knowledge that melanin blocks UV radiation and 
reduces the body’s ability to make Vitamin D. The ﬁndings related to total charges 
warrant further research to determine if patients are receiving the proper care for their 
illness and also not receiving unnecessary tests and procedures.
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OBJECTIVES: To assess the extent of reporting of bone mineral density (BMD) 
measurements and pharmacologic treatment among women over age 50 with osteo-
porosis in a nationally-representative Electronic Medical Record (EMR) database. The 
diagnosis of osteoporosis is based on a history of a prior fragility fracture or a low 
BMD, deﬁned as a T-score ≤ −2.5 on a dual energy x-ray absorptiometry (DEXA) 
test. DEXA is the standard measurement for bone density, which is usually calculated 
at the hip, and T-scores represent the number of standard deviations below (or above) 
the mean for young healthy women. Bisphosphonates are ﬁrst-line pharmacologic 
therapy for both women and men with T-scores diagnostic of osteoporosis. 
METHODS: The EMR database reviewed was the Medical Quality Improvement 
Consortium (MQIC) database from GE. This database contains EMR data collected 
from over 11,000 ambulatory providers in the United States and includes over 12 
million patients as of April, 2009. Records were reviewed for all women over age 50 
for the presence of a BMD test result and bisphosphonate prescriptions. RESULTS: 
Of 2,382,357 women over age 50, only 16,550 had a BMD test documented in their 
medical records. Of these, 16,505 had a T-score < −2.5, indicating osteoporosis. 
Among the women with a T-score diagnostic of osteoporosis, only 38% had a bisphos-
phonate prescription on record. Furthermore, nearly 10% of women with no BMD 
result on record were also prescribed bisphosphonates. CONCLUSIONS: The extent 
of under-reporting of BMD results in the outpatient records of these patients is difﬁcult 
to assess. Of those patients with a BMD test result available indicating osteoporosis, 
surprisingly few (38%) are receiving ﬁrst-line therapy with bisphosphonates. The 
possibility of underuse of BMD testing, and under treatment of osteoporosis, requires 
further investigation. In addition, the available data suggest that many providers may 
be prescribing bisphosphonates in the absence of a documented BMD measurement.
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HYALURONIC ACID MANAGEMENT OF KNEE OSTEOARTHRITIS: 
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OBJECTIVES: To observe, under actual conditions of use, the pain effect obtained, 
in the context of management of knee osteoarthritis, using hyaluronic acid (injectable 
route). METHODS: Pragmatic, longitudinal and prospective follow-up carried out by 
rheumatologists in the context of their daily professional activities; the investigator 
does not change the prescription or management habits. RESULTS: A total of 191 
patients are treated with hyaluronic acid. The average age is 64.72 years (± 7.34). 
Average pain during activities of daily living (ADL) was measured by means of a visual 
analogue scale (VAS). It is 50.12 ± 19.32 at inclusion. At 6 months, this same average 
pain measured under the same conditions is 36.95. At 6 months, this same average 
pain measured under the same conditions is 36.95 ± 25.10. A third measurement at 
12 months situates it at 38.10 ± 23.19. Pain during ADL is signiﬁcantly reduced 
between inclusion and month 6 (p = 0.0023) and between inclusion and month 12 (p 
= 0.0012). With regard to pain measured at rest, it was also measured at inclusion, 
at 6 and 12 months, by means of VAS. There is a signiﬁcant reduction in pain at rest 
between inclusion and 6 months (p = 0.0004) and the reduction between inclusion 
and month 12 is also signiﬁcant (p = 0.0007). At inclusion, 6 and 12 months, the 
average pain observed is 33.48 ± 22.45, 19.90 ± 19.88 and 21.64 ± 22.94, respectively. 
CONCLUSIONS: Our study, which assesses the effect on pain obtained in the context 
of management of subjects with knee osteoarthritis, using hyaluronic acid, showed a 
reduction in pain during ADL. This reduction in pain, which is signiﬁcant at 6 months, 
then perpetuated at 12 months, shows the relevance of the treatment.
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OBJECTIVES: To assess trends in the prescribing of conventional treatments in the 
pre-biologics era among Canadians with rheumatoid arthritis (RA). METHODS: Two 
retrospective cohort studies were conducted using the Quebec provincial physician 
billing, drug prescriptions and hospitalization databases (RAMQ and MEDECHO) 
from January 1, 1980 to December 31, 1999. All patients with RA (ICD 9, code 714) 
who received at least one of the following drugs: methotrexate, hydroxychloroquine, 
chloroquine, sulphasalazine, azathioprine, cyclophosphamide, cyclosporine, gold 
compounds, minocycline, penicillamine; NSAIDs and/or corticosteroids were recorded. 
Cohort entry was deﬁned as the date of the ﬁrst antirheumatic prescription or RA 
diagnosis. Study population was divided into each quinquennium. Patients with sys-
temic lupus erythematosus were excluded. RESULTS: Of 16,392 patients with RA 
diagnosis, 82.6% were receiving a ﬁrst DMARD prescription, 85.1% were receiving 
NSAIDs and 91.5% had corticosteroids during the study period. Most patients were 
adults (mean age 47 ± 15.6) and women (71%). DMARD users were older (59 ± 15.9 
vs. 42.5 ± 15.4, p < 0.05) and more DMARD users had severe disease. From 1980 to 
1989, the most prescribed DMARDs were gold compounds and minocycline while 
from 1990 to 1999 these were hydroxychloroquine and methotrexate. There was an 
increased frequency of DMARD use over time, from 12% in 1980 to 35.4% in 1999, 
and the time to DMARD initiation decreased from a mean of 1 year from presumed 
diagnosis in cohort 1 to 6 months in cohort 4. Most patients received DMARD as 
monotherapy. The use of DMARD combination was higher in cohort 4. Age, number 
of physician visits, heart failure and respiratory disease were associated with initiation 
of DMARD. CONCLUSIONS: During the two decades prior to the widespread use 
of biologic therapy, pharmacological management of adult rheumatoid arthritis in 
Canada had become more aggressive over time, with DMARDs being initiated earlier, 
and used increasingly in combination.
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OBJECTIVES: To validate Rheumatoid Arthritis Outcomes Analyzer, a data analysis 
tool with a user-friendly interface incorporating pharmacy, medical claims, and 
member eligibility information, by using data from two distinct commercially insured 
patient populations. METHODS: The framework for the Rheumatoid Arthritis Out-
comes Analyzer was developed based on published treatment guidelines and evidence-
based literature. The analyzer facilitates importation of claims and eligibility ﬁles and 
to perform outcomes analyses. Analysis of patients ≥18 years of age who received at 
least one traditional (non-biologic) or biologic DMARD medication between January 
2005 and December 2007 was conducted using HealthCore’s Integrated Research 
Database (Cohort #1) and a comparator commercial dataset (Cohort #2). All patients 
had at least two RA diagnoses (ICD-9 CM 714.0X) more than two months apart. 
RESULTS: A total of 25856 vs. 14383 RA patients, 19331 (74.8%) vs. 10869 female 
(75.6%), were identiﬁed in Cohorts #1 vs. #2 with a mean age of 56 and 55 years 
respectively. The mean Charlson Comorbidity Index was 2.00 (SD = 1.63) vs. 2.06 
(SD = 1.68). Prescription-level analyses revealed a total of 492195 vs. 263294 prescrip-
tions for DMARDs with 348074 (70.7%) vs. 183639 (69.7%) traditional, 132448 
(26.9%) vs. 77291 (29.4%) anti-TNF biologics and 11673 (2.4%) vs. 2364 (0.9%) 
non anti-TNF biologics. Concomitant corticosteroid use was identiﬁed in 15636 
(60.7%) vs. 8728 (60.7%) of patients in Cohorts #1 vs. #2 while NSAIDS and narcotic 
analgesics were used by 14538 (56.4%) vs. 8717 (60.6%) and 15024 (58.3%) vs. 
8113 (56.4%) respectively. Behavioral health medications were the next most preva-
lent concomitant medication used in 11571 (44.95) vs. 6197 (43.1%) of patients. 
CONCLUSIONS: Analytic tools like the Rheumatoid Arthritis Outcomes Analyzer 
will allow payers and policy makers to better understand utilization and treatment 
patterns easily and quickly. Replication and validation of outputs from these tools are 
important to establish the precision of results.
